Sign In

Getting to HBV Cure: The Path Forward

Date/Time 

  • Friday, October 20, 2-6 pm

Program Chairs  

  • Timothy M. Block, PhD
  • Jordan J. Feld, MD, MPH

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the role of new biomarkers for defining HBV disease activity.
  • Identify novel virological and immunological approaches to HBV therapy.
  • Recognize the challenges with trial design for different therapies in different populations.

Session Description/Needs Statement

There is a critical need for curative therapy for HBV. This program will systematically review the various approaches to achieving this goal. Attendees will gain a greater appreciation for the challenges in developing new HBV therapies and discover where new therapies will fit into the future treatment landscape for this disease.

Session I: Populations and Clinical Designs

  • Moderators: Jordan J. Feld, MD, MPH and Norah Terrault, MD, MPH, FAASLD

  • 2:05-2:15 pm
    Debate: How Many People Have HBV? We Overestimated the Burden
    Scott D. Holmberg, MD, MPH
  • 2:15-2:25 pm
    Debate: How Many People Have HBV? We Underestimated the Burden
    Robert G. Gish, MD, FAASLD
  • 2:25-2:40 pm
    Will New Diagnostics Improve Linkage to Care and Outcomes with Current Therapy?
    Mindie H. Nguyen, MD, FAASLD
  • 2:40-2:55 pm
    Redefining How We Assess Disease Activity – New Biomarkers For HBV
    Jorg Petersen, MD, PhD
  • 2:55-3:10 pm
    Picking the Right Target, The Right Population and The Right Endpoints
    Norah Terrault, MD, MPH
  • 3:10-3:30 pm
    Panel Discussion
  • 3:30-3:55 pm
    Break

Session II: Experimental Therapeutics

Moderators: Timothy M. Block, PhD and Fabien Zoulim, MD, PhD

  • 3:55-4:10 pm
    Virological Targets – From Entry to cccDNA
    Stephen Locarnini, PhD, MBBS
  • 4:10-4:25 pm
    Virological Targets – From Packaging Through Secretion
    Ju-Tao Guo, MD
  • 4:25-4:40 pm
    Immunological Therapy: Innate Approach
    Adam J. Gehring, PhD
  • 4:40-4:55 pm
    Immunological Therapy: Harnessing Adaptive Immunity
    Barbara Rehermann, MD
  • 4:55-5:20 pm
    Panel Discussion

Session III: Industry & Drug Discoverers Round Table

Moderators: Harry L.A. Janssen, MD, PhD and Carol L. Brosgart, MD

  • 5:20-5:25 pm
    Introduction of Panelists
  • 5:25 pm-5:55 pm
    Q&A Panelist
    Uri A. Lopatin, MD
  • 5:25-5:55 pm
    Q&A Panelist
    Raymond F. Schinazi, PhD
  • 5:25-5:55 pm
    Q&A Panelist
    Michael Sofia, PhD
  • 5:25-5:55 pm
    Q&A Panelist
    Bruce Given, MD
  • 5:25-5:55 pm
    Q&A Panelist
    Anuj Gaggar, MD, PhD
  • 5:55-6 pm
    Wrap Up